9 Comments
User's avatar
N.R98's avatar

This was fantastic!

Sleepy Dragon's avatar

Curious do you see the odd for ACI deal to go through lower now with JBLU trial? The stock seems hold out pretty well after it

Valorem Legal Research's avatar

I need to spend more time with it. You don’t have the same product class issue with ACI, which leads me to believe that divestitures (maybe a lot of them) could actually cure the harm. But it’s too early for me to have conviction.

South Sea Investing's avatar

Do you only look at US equities? Or would foreign legal situationships in foreign markets, e.g. the UK, Canada, also be considered?

Valorem Legal Research's avatar

I have looked at foreign companies with US-based litigations, but when it comes to foreign courts I don’t have much more of an edge than anyone else who’s willing to put in the work to understand another legal system

Marc's avatar

Love being a member of the sub. I am curious if you think there will be a SAVE or LQDA ruling first. My guess would be SAVE.

Valorem Legal Research's avatar

Hi Marc! I’d probably wager SAVE. I’m skeptical of a Rule 36 for LQDA, and J. Young has specifically said he’s keen to rule quickly in JBLU. Would put a likely window for JBLU in early to mid Jan and likely window for LQDA in late Jan to mid Feb.

PB's avatar

It's not really that the loss of consumer choice is a standalone harm; I think the argument is that the loss of the budget option specifically is a harm. I'm sceptical that the judge will put much weight in the affluent offset. IMO it will come down to whether he rules that other ulcc will fill the void in the budget option. That's the easy out.

User's avatar
Comment deleted
Dec 9, 2023
Comment deleted
Bill Huang's avatar

good hhi analysis i found here: https://jackedtothetits.substack.com/p/the-jblu-and-spirit-merger

no wonder hhi was not rlly mentioned in the trials